Niagen Bioscience Collaborates with USP to Establish First-Ever USP Monograph for Nicotinamide Riboside Chloride (NRCl), the Patented Form in Niagen®
Thursday, April 9, 2026 1 min read
Key Takeaway: Niagen Bioscience, Inc. has announced the publication of a United States Pharmacopeia (USP) dietary supplement ingredient monograph for Nicotinamide Riboside Chloride (NRCl), the patented form of nicotinamide riboside in its flagship product, Niagen®. This milestone underscores the scientific credibility of Niagen and the company's commitment to healthy aging.
Price reaction · baseline $4.6 (2026-04-08 close) · hit after-hours · clean, no other NAGE news in the window
day 0 close · peak
-2.6%
Market Sentiment Analysis
POSITIVE FACTORS
Establishment of the first-ever USP monograph for NRCl.
Highlights the scientific rigor behind Niagen.
Affirms Niagen Bioscience's leadership in NAD+ research.
Full Press Release Details
LOS ANGELES--(BUSINESS WIRE)---- $NAGE #Biotech--Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announces that Nicotinamide Riboside Chloride (NRCl), the patented form of nicotinamide riboside in the Company’s flagship ingredient, Niagen®, now has a published United States Pharmacopeia (USP) dietary supplement ingredient monograph. This monograph reflects the scientific rigor behind Niagen and establishes
Frequently Asked Questions
What is the significance of the USP monograph for NRCl?
The USP monograph establishes the scientific credibility of Nicotinamide Riboside Chloride as a dietary supplement ingredient.
What company is behind the NRCl monograph?
Niagen Bioscience, Inc. is the company that announced the publication of the NRCl monograph.
What does NRCl stand for?
NRCl stands for Nicotinamide Riboside Chloride, a patented form of nicotinamide riboside.
What is Niagen®?
Niagen® is the flagship ingredient of Niagen Bioscience, focused on promoting healthy aging.